---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-086918"
form_type: "8-K"
ticker: "NEUP"
cik: "0001191070"
company_name: "Neuphoria Therapeutics Inc."
filed_at: "2024-10-10T23:59:59+00:00"
generated_at: "2026-05-30T16:19:01.738005+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Bionomics director Aaron Weaver resigns from board effective Oct 9, 2024

## Summary
- Aaron Weaver resigned from Bionomics' Board of Directors on October 9, 2024.
- Resignation does not involve any disagreement on operations, policies, or practices.
- Weaver served on the board for four years; company thanked him and wished him well.

## SEC filing metadata
- accession: 0001213900-24-086918
- form_type: 8-K
- ticker: NEUP
- cik: 0001191070
- company_name: Neuphoria Therapeutics Inc.
- filed_at: 2024-10-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1191070/000121390024086918/0001213900-24-086918-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1191070/000121390024086918/ea021734401-8k_bionomics.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-086918
- JSON: https://secwatch.observer/filing/0001213900-24-086918.json
- Plain text: https://secwatch.observer/filing/0001213900-24-086918.txt

## Key facts
- Executive change
  Aaron Weaver resigned as Director at Neuphoria Therapeutics Inc..
  - Action: resigned
  - Role: Director
  source text: On October 9, 2024, Mr. Aaron Weaver, a member of the Board of Directors of Bionomics Limited (the “Company”), provided the Company’s board with notice that he was resigning from the Board of Directors, effective October 9, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1191070/000121390024086918/0001213900-24-086918-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.